SOURCE: Paragon Financial Limited

Paragon Financial Limited

September 22, 2011 08:16 ET

Medical Supply Makers Look for FDA Clarity

The Paragon Report Provides Equity Research on Antares Pharma & Boston Scientific

NEW YORK, NY--(Marketwire - Sep 22, 2011) - The Paragon Report examines investing opportunities in the Medical Equipment & Supplies industry and provides equity research on Antares Pharma, Inc. (AMEX: AIS) and Boston Scientific Corporation (NYSE: BSX). Access to the full company reports can be found at:

www.paragonreport.com/AIS

www.paragonreport.com/BSX

Profit margins throughout the medical supplies industry are being hurt from several directions. Companies have had to lower device prices to combat the high unemployment rates, while sweeping healthcare reform that came into effect last year has also crimped profits. In addition to margin concerns, the FDA's medical device approval process continues to confuse the industry.

The Institute of Medicine recently recommended that the US government create a new system of approving medical devices because the current system does not guarantee the products are safe. The panel from the Institute for Medicines also said the FDA should abandon a process that allows for medical devices to be approved if the manufacturers prove they are similar to devices that are already on the market.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Medical Equipment & Supplies industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Antares Pharma focuses on self-injection pharmaceutical products and technologies, and topical gel-based products and offers injection devices including Zomajet 2 Vision and Zomajet Vision X. In the most recent quarter the company announced an exclusive licensing agreement with Watson Pharmaceuticals, for the commercialization of Anturol gel, for treatment of patients with overactive bladder, which is currently under review by the Food and Drug Administration.

Several medical supply makers are looking to emerging markets as a means to supplement the tepid growth of domestic medical instrument and supply markets.

Boston Scientific CEO J. Raymond Elliott recently said the company will be "putting a big emphasis on international" going forward. Boston Scientific is investing significantly in its direct presence in India, with an emphasis on critically important therapeutic areas such as Interventional Cardiology, Cardiac Rhythm Management and Electrophysiology, Peripheral Interventions, Endoscopy, Urology, and Women's Health.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer